Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 2/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397383 | 1.00 | CYP1A2 (0.54) | CYP1A2NAMPTTAAR1FAAHL3MBTL1 | |
| SCHEMBL436307 | 0.95 | CYP1A2 (0.56) | CYP1A2NAMPTTAAR1FAAHL3MBTL1 | |
| SCHEMBL401761 | 0.90 | CYP1A2 (0.55) | CYP1A2NAMPTTAAR1FAAHL3MBTL1 | |
| SCHEMBL403383 | 0.89 | CYP1A2 (0.43) | CYP1A2NAMPT | |
| SCHEMBL403382 | 0.89 | CYP1A2 (0.43) | CYP1A2NAMPT | |
| SCHEMBL402888 | 0.87 | CYP1A2 (0.52) | CYP1A2NAMPTTAAR1CACNA1GCACNA1H | |
| SCHEMBL402335 | 0.84 | CYP1A2 (0.45) | CYP1A2 | |
| SCHEMBL401885 | 0.83 | CYP1A2 (0.36) | CYP1A2 | |
| SCHEMBL400588 | 0.83 | CYP1A2 (0.52) | CYP1A2NAMPTTAAR1FAAHL3MBTL1 | |
| SCHEMBL401479 | 0.82 | CYP1A2 (0.51) | CYP1A2NAMPTTAAR1FAAHHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2015-01-01 | — | — | US | claimed |
| US-8110595-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INC. (US) | 2012-02-07 | — | — | US | claimed |
| US-20090036447-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. (US) | 2009-02-05 | — | — | US | claimed |
| US-9150564-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2015-01-01 | — | — | US | disclosed |
| US-8871769-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871768-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140038983-A1 | UREAS AND THEIR USE IN THE TREATMENT OF HEART FAILURE | CYTOKINETICS, INCORPORATED (US) | 2014-02-06 | — | — | US | disclosed |
| US-20130324549-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-8513257-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INCORPORATED (US) | 2013-08-20 | — | — | US | disclosed |
| US-8445495-B2 | Certain Chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | CYTOKINETICS, INC. | 2012-07-05 | — | — | US | disclosed |
| US-8110595-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8101617-B2 | Disubstituted ureas and uses thereof in treating heart failure | AMGEN, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100029680-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090099198-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090036447-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | TNNI3, TNNT2, MYLK2 | CYP1A2 3816/4885NAMPT 3070/4885TAAR1 4240/4885 |
| US-20090099198-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | CYP1A2 4662/4885NAMPT 3383/4885TAAR1 4657/4885 |
| US-20140038983-A1 | UREAS AND THEIR USE IN THE TREATMENT OF HEART FAILURE | TNNI3, TNNT2, MYLK2 | CYP1A2 3816/4885NAMPT 3070/4885TAAR1 4240/4885 |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | CYP1A2 4662/4885NAMPT 3383/4885TAAR1 4657/4885 |
| US-20130324549-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNI3, TNNT2, MYLK2 | CYP1A2 4402/4885NAMPT 3645/4885TAAR1 4458/4885 |
| US-20100029680-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, MYLK2 | CYP1A2 4402/4885NAMPT 3645/4885TAAR1 4458/4885 |
| US-20090036447-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | CYP1A2 4662/4885NAMPT 3383/4885TAAR1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.